Entera Bio Ltd.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $42.0K | $82.0K | $42.0K |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $42.0K | $82.0K | $42.0K |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | — | 0.0% | 0.0% | 0.0% |
| Operating Expenses | ||||||||
| Research & Development | $3.2M | $2.3M | $1.7M | $1.6M | $1.5M | $1.1M | $1.2M | $1.5M |
| SG&A Expense | $124.0K | $128.0K | $50.0K | $122.0K | $103.0K | $123.0K | $-1.2M | $62.0K |
| Operating Income | $-4.6M | $-3.5M | $-3.0M | $-3.3M | $-2.7M | $-2.6M | $-2.3M | $-3.0M |
| Operating Margin | — | — | — | — | — | -6,102.4% | -2,850.0% | -7,192.9% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | $-3.0M |
| Income Tax Expense | — | — | — | — | — | — | — | $0 |
| Net Income | $-7.3M | $-3.5M | $-3.0M | $-3.2M | $-2.7M | $-2.6M | $-2.4M | $-3.0M |
| Net Margin | — | — | — | — | — | -6,111.9% | -2,875.6% | -7,192.9% |
| EPS (Basic) | $0.14 | $0.07 | $0.06 | $0.07 | $0.06 | $0.06 | $0.06 | $0.08 |
| EPS (Diluted) | $0.14 | $0.07 | $0.06 | $0.07 | $0.06 | $0.06 | $0.06 | $0.08 |
| Shares Outstanding (Basic) | 50.5M | 47.8M | 46.2M | 47.1M | 46.8M | 43.4M | 37.7M | 37.6M |
| Shares Outstanding (Diluted) | 50.5M | 47.8M | 46.2M | 47.1M | 46.8M | 43.4M | 37.7M | 37.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |